Compare Viatris Inc (VTRS) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Xcel Energy Inc — how do they compare? Viatris Inc trades at $16.45 (market cap $19.09B), while Xcel Energy Inc trades at $76.33 (market cap $48.02B). The key difference: Xcel Energy Inc is far larger — about 2.5× Viatris Inc's market cap, and Xcel Energy Inc pays the higher dividend (3.08%). Which is the better fit depends on your goals.
| VTRS | XEL | |
|---|---|---|
Market Cap | $19.09B | $48.02B |
Sector | Health | Utilities |
52-Week High | $17.86 | $83.91 |
52-Week Low | $9.49 | $72.05 |
Enterprise Value | $31.21B | $86.33B |
Dividend Yield | 2.89% | 3.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $16.61, down 1.6% on the day, with a bullish technical signal but mixed moving averages. The company reported Q2 2026 EPS of $0.69, beating estimates, and revenue growth of 5% year-over-year. Despite negative net income margins, strong cash flow generation supports dividends and buybacks. Recent news highlights pipeline progress and a higher 2026 outlook.
Outlook: Viatris shows operational strength with consistent earnings beats and cash flow, but high P/E and negative profitability pose risks. Investment opportunity lies in deleveraging and pipeline advancements, while headwinds include generic drug pricing pressure and regulatory uncertainty. Analyst sentiment is mixed with a hold-heavy consensus.
XEL trades at $76.88, up 1.53% today, with a bearish technical signal but strong fundamentals including a 24% EPS beat in Q2 2026. The company shows consistent revenue growth, a 15.28% net income margin, and a robust $70B+ investment plan for 2026-2030. Recent news highlights institutional buying and dividend stability, though technical indicators point to near-term resistance.
Outlook is positive with a consensus price target of $92.00, implying 20% upside, supported by earnings growth and strategic investments. Risks include high capital expenditures, rising debt levels, and regulatory pressures from wildfire lawsuits. The stock offers a stable income play with growth potential but faces execution risks on its expansive spending plan.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
